Iman Osman

Riyadh Armed Forces Hospital — Saudi Arabia

Medicine · Health Sciences

71h-index19.0kcitations715works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cutaneous Melanoma Detection and Management(171), Melanoma and MAPK Pathways(157), Cancer Immunotherapy and Biomarkers(144), Immunotherapy and Immune Responses(106), CAR-T cell therapy research(90)

Publications708 total

Supplementary Data1 from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma
2025Open Access
Supplementary Figures1 from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma
2025Open Access
Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma
Clinical Cancer Research·2025
Approximate Bilevel Graph Structure Learning for Histopathology Image Classification
arXiv (Cornell University)·2025Open Access
Table S5 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
2025Open Access
Figure S5 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
2025Open Access
Table S3 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
2025Open Access
Table S8 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
2025Open Access
Data from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
2025Open Access
Table S7 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
2025Open Access
Tables S1 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
2025Open Access
Table S2 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
2025Open Access
Table S4 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
2025Open Access
Table S6 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
2025Open Access
Table S10 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
2025Open Access
Figure S2 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
2025Open Access
Table S11 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
2025Open Access
Figure S3 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
2025Open Access
Figure S4 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
2025Open Access
Table S9 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
2025Open Access
page 1 of 36Next →

Frequent Co-authors

David Polsky(14), Anna C. Pavlick(13), Eva Hernando(12), Farbod Darvishian(12), Richard L. Shapiro(10), Russell S. Berman(9), Miguel F. Segura(6), Douglas Hanniford(6), Nina Bhardwaj(6), Howard I. Scher(6), Paul J. Christos(6), Carlos Cordon‐Cardo(5), Madhu Mazumdar(5), Judy Zhong(5), Jan Zakrzewski(4), Klaus J. Busam(4), Sílvia Menéndez(3), Amy Rose(3), Ilana Belitskaya‐Lévy(3), Aristotelis Tsirigos(3)